Sensitization to Staphylococcus aureus toxins in Severe Asthma. The Belgian IgE (BEIgE) study.
Conclusion: Patients with SA and StA-monosensitization display a ‘Type 2’ (T2) airways inflammatory profile and may therefore represent a T2 SA subgroup which is incorrectly considered as ‘non-sensitized’; testing for StA toxins may therefore be indicated in this group of patients. Further prospective studies are needed to establish whether they might benefit from anti-IgE therapy. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Schleich, F., Maury, E., Bachert, C., Jansen, M., Gurdain, S., Van Schoor, J. Tags: Allergy and immunology Source Type: research
World-wide variation in the proportion of patients eligible for asthma biologics: a systematic review
Conclusion: The proportion of patients eligible for biologic therapy vary amongst asthma populations world-wide. This is related to clinical differences in the patient populations and biologic eligibility criteria. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Yang, F., Salciccioli, J. D., Mcclean, M., Bloom, C. Tags: Epidemiology Source Type: research
Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for Omalizumab: a single centre experience
Conclusion: Mepolizumab appeared to be associated with a reduction in the hospitalisation rate for asthma and a reduction in daily steroid burden. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Lim, Y. T., Williams, T., Langley, R., Weir, E. Tags: Paediatric asthma and allergy Source Type: research
Differential miRNA expression could identify responders to biologic therapy in severe uncontrolled asthma
Conclusions: The differential expression of serum miRNAs miR-6803-5p, miR-4281 and miR-7108-5p could identify responders to BT. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Iglesias Coma, A., Shafiek, H., Muncunill, J., Fleischer, A., Valera, J. L., Lopez, M., Martinez, R., Martin, A., Canaves, L., Riera, L., Mosteiro, M., Escribano, I., Perez De Llano, L., G Cosio, B. Tags: Molecular pathology and functional genomics Source Type: research
Benralizumab effectiveness in patients with severe asthma regardless of prior biologic use: A real-world Canadian experience
Conclusions: Significant reductions in exacerbations and BEC, and preserved lung function were observed at 48 weeks post benralizumab initiation for both biologic-experienced and biologic-naïve patients with SEA. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Nair, P., Kayaniyil, S., St. Pierre, C., Osenenko, K., Li, T., Johnston, K., Lacuesta, G., Khan, I., Anees, S., Lai, Y. H., Rahimi, P., Dhawan, V., Dorscheid, D., Cote, A. Tags: Airway pharmacology and treatment Source Type: research
Intramuscular triamcinolone for access to biologic therapy in asthma- a retrospective cohort analysis
Conclusions: This retrospective cohort analysis shows the viability of using a trial of triamcinolone to identify those patients who would benefit from biologics. This is the first reported evidence of positive clinical outcomes in this patient cohort. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Chadwick, A., Prior, K., Vyas, A. Tags: Airway pharmacology and treatment Source Type: research
Biologic agents licensed for severe asthma: A systematic review and meta-analysis of randomised controlled trials
Conclusions: Biologic agents reduced exacerbations and symptoms, increased lung function, and improved quality of life in severe asthma, with acceptable safety profile. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Kyriakopoulos, C., Gogali, A., Markozannes, G., Potonos, D., Bellou, V., Ntritsos, G., Kostikas, K. Tags: Airway pharmacology and treatment Source Type: research
Real life biological therapy effectiveness in patients with severe eosinophilic asthma: a comparison with randomized trial
Conclusions: Patients enrolled in the RCTs don’t reflect the heterogeneity of the SEA population, which typically suffers from other comorbidities. This makes clear the need to take strides toward "patient-tailored" medicine. Our RL experience is in line with the results of RCTs, showing that the latter are generalizable. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Calo, O., Lo Muzio, G., Scarano, P., Cisternino, C., Capuano, V., Steffanina, A., De Filippis, F., Sanna, A., Leporini, M. T., Palange, P., Graziani, E. Tags: Airway pharmacology and treatment Source Type: research
Late Breaking Abstract - Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: Integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
Conclusion: Clinical remission is a realistic, sustainable goal up to 2 years for pts with SEA receiving benralizumab, regardless of prior biologic experience.Funding: AstraZeneca (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Pelaia, G., Jackson, D. J., Nair, P., Emmanuel, B., Tran, T. N., Menzies-Gow, A., Watt, M., Kayaniyil, S., Boarino, S., Nuevo, J., Pardal, M., Shavit, A., Shih, V., Cohen, D., Loureiro, C., Padilla-Galo, A. Tags: Airway pharmacology and treatment Source Type: research
Effect of add-on therapies (mepolizumab, omalizumab or azithromycin) on asthma remission in severe asthma
Conclusion: Twelve months treatment with add-on therapies, mepolizumab, omalizumab or azithromycin, induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target in severe asthma and future studies should consider remission as an outcome measure. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Thomas, D., Mcdonald, V., Stevens, S., Harvey, E., Baraket, M., Bardin, P., Bowden, J., Bowler, S., Chien, J., Chung, L. P., Gillman, A., Hew, M., Hodge, S., James, A., Jenkins, C., Katelaris, C., Katsoulotos, G., Langton, D., Lee, J., Marks, G., Peters, Tags: Airway pharmacology and treatment Source Type: research
Treating severe IgE mediated allergic adult asthmatics with omalizumab outside the dosing table
Conclusion: Our results confirm and reaffirm the decision to treat severe IgE-mediated asthmatic patients with an IgE level and/or weight outside the dosing chart with the maximum recommended dose with good clinical outcomes, safety and tolerability profiles. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Ceci Bonello, E., Gouder, C. Tags: Airway pharmacology and treatment Source Type: research
Agreement and discrepancies between past prescribing decisions and future prescribing preferences: An EU outlook
Conclusions: Mepolizumab providers preferred a future biologic switch within the same MOA, while those treating patients on other biologics favored a different MOA.Funding: GSK:218228 (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Valliant, S., Harvey, J., Zhang, S., Emeanuru, K., Brunini Pitta Palhares, K., Andre, M., Alfonso-Cristancho, R. Tags: Airway pharmacology and treatment Source Type: research
Biologic treatment patterns of severe asthma patients in the EU-4 and the UK
Conclusions: Omalizumab was the most prescribed index biologic across all countries, except the UK. Biologic selection for patients who switched varied, however benralizumab or dupilumab were favored across all, except Spain.Funding: GSK:218228 (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Valliant, S., Harvey, J., Zhang, S., Emeanuru, K., Brunini Pitta Palhares, K., Andre, M., Alfonso-Cristancho, R. Tags: Airway pharmacology and treatment Source Type: research
Real-world experience of biologics use and switching among adults with severe asthma at a tertiary care centre in United Arab Emirates
Conclusion: Real-world switching of biologics occurred in 1 in 5 patients (20%) in this UAE population with high insurance premium and in 7% patients twice. Switching is becoming increasingly common with approval of additional biologics. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Alkassar, Y., Abbas, A., Hassan, A., Raidullah, E. R., Al Maashari, R., Najib, M., Tufail, M. T. Tags: Airway pharmacology and treatment Source Type: research
An algorithm to identify patients with T2 diseases and Chronic Spontaneous Urticaria treated with biologics in outpatient care setting using a dynamic dispensing database
Conclusion: The algorithm was able to identify patients with T2 diseases or CSU under Bx treatments. This tool may help to follow the evolution of prescription patterns in the future. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Charriot, J., Descamps, V., Jankowski, R., Maravic, M., Bourdin, A. Tags: Airway pharmacology and treatment Source Type: research
